MCID: CHG001
MIFTS: 72

Chagas Disease

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Chagas Disease

MalaCards integrated aliases for Chagas Disease:

Name: Chagas Disease 12 77 54 60 56 44 3 45 15 74
American Trypanosomiasis 12 77 54 60 3 17
Chagas' Disease with Digestive System Involvement 12
Chagas' Disease with Nervous System Involvement 12
Chagas' Disease with Other Organ Involvement 12
South American Trypanosomiasis 54
New World Trypanosomiasis 54
Chagas' Disease 12

Characteristics:

Orphanet epidemiological data:

60
american trypanosomiasis
Inheritance: Not applicable; Prevalence: 6-9/10000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare infectious diseases


Summaries for Chagas Disease

NIH Rare Diseases : 54 Chagas disease is caused by the parasite, Trypanosoma cruzi. The triatomine bug, which can carry the parasite, most often bites a person's face and therefore is more commonly known as the "kissing bug". When a triatomine bug infected with Trypanosoma cruzi bites, it can leave behind infected waste which can be spread into the person's eyes, nose, or a wound. Chagas disease can also spread through contaminated food, a blood transfusion, a donated organ, or from mother to baby during pregnancy. Symptoms may include fever, flu-like symptoms, a rash, or swollen eyelid. Early symptoms usually go away without treatment, but can last a few weeks or months. However, if not treated in the early phase, the parasite can become active again years later. In fact, 20-30% of infected people will later develop serious problems affecting their heart, intestines, or espophagus. This risk is greater for those with a weakened immune system. Chagas disease is common in Latin America, but not in the United States. The two drugs used to treat Chagas disease are nifurtimox and benznidazole. On August 30, 2017, the FDA approved benznidazole to treat Chagas disease in children between the ages of 2 to 12 years old. Nifurtimox may also used to treat Chagas disease. Although not FDA approved, nifurtimox can be obtained for the treatment of Chagas disease in the United States through special CDC studies. Similarly, benznidazole is also available through special CDC studies for those with Chagas disease whose treatment is deemed necessary by their doctor but whose age falls outside FDA approval.

MalaCards based summary : Chagas Disease, also known as american trypanosomiasis, is related to trypanosomiasis and sleeping sickness, and has symptoms including fever and pruritus. An important gene associated with Chagas Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Aspirin and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and t cells, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis.

MedlinePlus : 44 Chagas disease is caused by a parasite. It is common in Latin America but not in the United States. Infected blood-sucking bugs, sometimes called kissing bugs, spread it. When the bug bites you, usually on your face, it leaves behind infected waste. You can get the infection if you rub it in your eyes or nose, the bite wound or a cut. The disease can also spread through contaminated food, a blood transfusion, a donated organ or from mother to baby during pregnancy. If you notice symptoms, they might include Fever Flu-like symptoms A rash A swollen eyelid These early symptoms usually go away. However, if you don't treat the infection, it stays in your body. Later, it can cause serious intestinal and heart problems. A physical exam and blood tests can diagnose it. You may also need tests to see whether the disease has affected your intestines and heart. Medicines can kill the parasite, especially early on. You can also treat related problems. For example, a pacemaker helps with certain heart complications. There are no vaccines or medicines to prevent Chagas disease. If you travel to areas where it occurs, you are at higher risk if you sleep outdoors or in poor housing conditions. It is important to use insecticides to prevent bites, and practice food safety. Centers for Disease Control and Prevention

CDC : 3  

Wikipedia : 77 Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the... more...

Related Diseases for Chagas Disease

Diseases related to Chagas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 406)
# Related Disease Score Top Affiliating Genes
1 trypanosomiasis 31.9 CALR CCL2 CCL3 IFNG IL10 IL1B
2 sleeping sickness 31.2 IL10 IL6 NOS2
3 idiopathic achalasia 31.1 IL10 NOS2 TNF
4 leishmaniasis 30.9 IFNG IL10 IL1B NOS2 TLR2 TLR4
5 mucocutaneous leishmaniasis 30.7 CCR5 IL10 TNF
6 cysticercosis 30.6 IL1B IL6 TLR4
7 esophagitis 30.6 IL1B IL6 TGFB1
8 cutaneous leishmaniasis 30.6 IFNG IL10 TLR2 TLR4 TNF
9 salmonellosis 30.4 IFNG IL1B TLR4
10 membranous nephropathy 30.3 ACE TGFB1 TNF
11 myocarditis 30.2 IL6 NOS2 NPPB TNF
12 visceral leishmaniasis 30.2 IFNG IL10 IL2 NOS2 TLR2 TLR4
13 schistosomiasis 30.1 CCL3 IFNG IL10 IL2 TNF
14 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.1 CCR5 IFNG IL10 IL2
15 autoimmune disease 30.0 IFNG IL10 IL1B IL2 IL6 TNF
16 leprosy 3 30.0 IFNG IL10 IL2 TLR2 TNF
17 typhoid fever 29.9 IFNG IL1B IL6 TLR4 TNF
18 pertussis 29.9 IL10 IL1B IL6 TLR4 TNF
19 lyme disease 29.9 IL1B IL6 TLR2 TNF
20 acquired immunodeficiency syndrome 29.9 CCL3 CCR5 IFNG IL10 IL1B IL2
21 toxoplasmosis 29.7 CCR5 IFNG IL10 IL1B IL6 TLR2
22 sleep apnea 29.7 ACE IL1B IL6 NPPB TNF
23 filariasis 29.7 IFNG IL10 IL2 IL6 TLR2 TLR4
24 human immunodeficiency virus infectious disease 29.4 CCL3 CCR5 IFNG IL10 IL2 IL6
25 systolic heart failure 29.4 ACE ADRB1 IL6 NPPB
26 pneumonia 29.4 CCL2 CCL3 IL10 IL1B IL6 TLR2
27 malaria 29.4 CCL2 CCL3 IFNG IL10 IL1B IL2
28 arteries, anomalies of 29.3 ACE CCL2 IL1B IL6 NPPB TNF
29 heart disease 29.1 ACE ADRB1 IL10 IL1B IL6 NPPB
30 dilated cardiomyopathy 28.8 ACE ADRB1 CALR IL10 IL1B IL6
31 systemic lupus erythematosus 28.5 ACE CALR CCL2 CCR5 IFNG IL10
32 myocardial infarction 28.2 ACE ADRB1 CCL2 CCR5 IL10 IL1B
33 cephalosporin allergy 10.6 IFNG IL10
34 hyperlucent lung 10.6 IFNG IL10
35 multifocal choroiditis 10.6 IL10 TNF
36 punctate inner choroidopathy 10.6 IL10 TNF
37 tropical endomyocardial fibrosis 10.6 IL10 TNF
38 inflammatory bowel disease 25, autosomal recessive 10.6 IL10 TGFB1
39 oral tuberculosis 10.6 IL2 TNF
40 juvenile myasthenia gravis 10.6 IL10 TGFB1
41 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 IL6 TNF
42 exudative glomerulonephritis 10.6 IL1B TNF
43 autoimmune atherosclerosis 10.6 ACE IL10
44 skin sarcoidosis 10.6 ACE TNF
45 uveoparotid fever 10.6 ACE TNF
46 purulent labyrinthitis 10.6 CCL2 IL1B
47 leukomalacia 10.6 IL6 TNF
48 scorpion envenomation 10.6 IL6 TNF
49 subacute cutaneous lupus erythematosus 10.5 ACE TNF
50 recurrent corneal erosion 10.5 IL1B IL6

Graphical network of the top 20 diseases related to Chagas Disease:



Diseases related to Chagas Disease

Symptoms & Phenotypes for Chagas Disease

Human phenotypes related to Chagas Disease:

60 33 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 60 33 frequent (33%) Frequent (79-30%) HP:0001744
2 hepatomegaly 60 33 frequent (33%) Frequent (79-30%) HP:0002240
3 fever 60 33 frequent (33%) Frequent (79-30%) HP:0001945
4 dyspnea 60 33 frequent (33%) Frequent (79-30%) HP:0002094
5 arrhythmia 60 33 frequent (33%) Frequent (79-30%) HP:0011675
6 thromboembolism 60 33 frequent (33%) Frequent (79-30%) HP:0001907
7 pallor 60 33 frequent (33%) Frequent (79-30%) HP:0000980
8 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
9 cardiomyopathy 60 33 frequent (33%) Frequent (79-30%) HP:0001638
10 myalgia 60 33 frequent (33%) Frequent (79-30%) HP:0003326
11 headache 60 33 frequent (33%) Frequent (79-30%) HP:0002315
12 diarrhea 60 33 frequent (33%) Frequent (79-30%) HP:0002014
13 myocarditis 60 33 frequent (33%) Frequent (79-30%) HP:0012819
14 skin rash 60 33 frequent (33%) Frequent (79-30%) HP:0000988
15 cough 60 33 frequent (33%) Frequent (79-30%) HP:0012735
16 periorbital edema 60 33 frequent (33%) Frequent (79-30%) HP:0100539
17 lymphadenopathy 60 33 frequent (33%) Frequent (79-30%) HP:0002716
18 localized skin lesion 60 33 frequent (33%) Frequent (79-30%) HP:0011355
19 autoimmune antibody positivity 60 33 frequent (33%) Frequent (79-30%) HP:0030057
20 congestive heart failure 60 33 occasional (7.5%) Occasional (29-5%) HP:0001635
21 aganglionic megacolon 60 33 occasional (7.5%) Occasional (29-5%) HP:0002251
22 achalasia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002571
23 abnormal large intestine physiology 60 33 occasional (7.5%) Occasional (29-5%) HP:0012700
24 encephalitis 60 33 very rare (1%) Very rare (<4-1%) HP:0002383
25 peripheral neuropathy 60 33 very rare (1%) Very rare (<4-1%) HP:0009830
26 edema 60 Frequent (79-30%)
27 abnormality of the nervous system 60 Very rare (<4-1%)

UMLS symptoms related to Chagas Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Chagas Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE IL10 IL1B IL2 NOS2 TGFB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE IL10 IL1B IL2 NOS2 TGFB1

MGI Mouse Phenotypes related to Chagas Disease:

47 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
2 growth/size/body region MP:0005378 10.43 ACE ADRB1 CALR CYP51A1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.41 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
4 immune system MP:0005387 10.4 ACE CCL2 CCR5 CYP51A1 IFNG IL10
5 behavior/neurological MP:0005386 10.38 ACE CCR5 IFNG IL10 IL2 IL6
6 mortality/aging MP:0010768 10.38 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
7 hematopoietic system MP:0005397 10.36 ACE CCR5 IFNG IL10 IL1B IL2
8 cellular MP:0005384 10.33 CALR CCR5 IFNG IL10 IL2 IL6
9 digestive/alimentary MP:0005381 10.32 CCR5 CYP51A1 IFNG IL10 IL2 IL6
10 endocrine/exocrine gland MP:0005379 10.27 ACE ADRB1 IFNG IL10 IL2 IL6
11 muscle MP:0005369 10.27 ADRB1 CALR CCR5 CYP51A1 IFNG IL10
12 liver/biliary system MP:0005370 10.24 ACE CCR5 IFNG IL10 IL2 IL6
13 adipose tissue MP:0005375 10.21 ACE ADRB1 IL6 NOS2 TGFB1 TLR2
14 integument MP:0010771 10.21 IFNG IL10 IL1B IL6 NOS2 NTRK1
15 neoplasm MP:0002006 10.21 ACE CCR5 IFNG IL10 IL1B IL2
16 nervous system MP:0003631 10.18 CALR CCR5 IFNG IL10 IL1B IL6
17 craniofacial MP:0005382 10.13 CYP51A1 IFNG IL10 IL1B NOS2 TGFB1
18 reproductive system MP:0005389 9.96 ACE CCR5 IFNG IL10 IL2 IL6
19 no phenotypic analysis MP:0003012 9.91 ADRB1 CYP51A1 IFNG IL10 IL2 NTRK1
20 renal/urinary system MP:0005367 9.87 ACE IFNG IL6 NOS2 TGFB1 TLR2
21 respiratory system MP:0005388 9.81 IFNG IL10 IL2 IL6 NOS2 TGFB1
22 skeleton MP:0005390 9.7 ADRB1 CYP51A1 IFNG IL10 IL1B IL6
23 vision/eye MP:0005391 9.32 CCR5 IFNG IL10 IL2 IL6 NOS2

Drugs & Therapeutics for Chagas Disease

Drugs for Chagas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Enalaprilat Approved Phase 4 76420-72-9 6917719
3
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
4
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
5
Warfarin Approved Phase 4 81-81-2 54678486 6691
6
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
7
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3 147127-20-6 464205
8
Zidovudine Approved Phase 4 30516-87-1 35370
9
Didanosine Approved Phase 4 69655-05-6 50599
10
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
11
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
12
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
13
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
14
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
15
Coumarin Experimental Phase 4 91-64-5 323
16 Antipyretics Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 Platelet Aggregation Inhibitors Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Antirheumatic Agents Phase 4,Phase 2
21 Fibrinolytic Agents Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Analgesics Phase 4,Phase 3
24 Analgesics, Non-Narcotic Phase 4,Phase 3
25 Peripheral Nervous System Agents Phase 4,Phase 3
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Benzonidazole Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Adrenergic Agents Phase 4,Phase 3
33 Neurotransmitter Agents Phase 4,Phase 3
34 Protective Agents Phase 4,Phase 3
35 Adrenergic alpha-Antagonists Phase 4
36 HIV Protease Inhibitors Phase 4,Phase 3
37 Adrenergic alpha-1 Receptor Antagonists Phase 4
38 Antihypertensive Agents Phase 4,Phase 3
39 Vasodilator Agents Phase 4,Phase 3,Not Applicable
40 Natriuretic Peptide, Brain Phase 4
41 calcium channel blockers Phase 4
42 Adrenergic Antagonists Phase 4,Phase 3
43 Calcium, Dietary Phase 4
44 Antioxidants Phase 4,Phase 3
45 Adrenergic beta-Antagonists Phase 4,Phase 3
46 Angiotensin-Converting Enzyme Inhibitors Phase 4
47 Hormones Phase 4,Phase 2
48
protease inhibitors Phase 4,Phase 3
49 Anticoagulants Phase 4
50 Atazanavir Sulfate Phase 4

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Unknown status NCT01650792 Phase 4 Aspirin
2 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4 Benznidazole
3 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Completed NCT01678599 Phase 4 Benznidazole
4 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Completed NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
5 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
6 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
7 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
8 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed NCT00084136 Phase 4 Atazanavir;Didanosine (enteric-coated);Efavirenz;Emtricitabine;Emtricitabine/Tenofovir disoproxil fumarate;Lamivudine/Zidovudine
9 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
10 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
11 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
12 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
13 Physical Exercise Program in Chronic Chagas Heart Disease Completed NCT02517632 Phase 3
14 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
15 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
16 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
17 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
18 Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Completed NCT01348308 Phase 3 Maraviroc (Celsentri);Placebo
19 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
20 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
21 A Trial Testing Amiodarone in Chagas Cardiomiopathy Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
22 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
23 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Active, not recruiting NCT01435018 Phase 3 Etoposide (ET);Bleomycin and Vincristine (BV);Paclitaxel (PTX);Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
24 Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age Not yet recruiting NCT03672487 Phase 3 Benznidazole;Placebo Oral Tablet
25 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
26 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
27 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
28 Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
29 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
30 Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
31 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
32 Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease Recruiting NCT03587766 Phase 2 Fexinidazole;Placebo Oral Tablet
33 Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. Recruiting NCT03191162 Phase 2 Benznidazole
34 Colchicine for Patients With Chagas´ Disease( B1 Stage) Recruiting NCT03704181 Phase 2 Colchicine 0.5 MG twice day for one year;Placebo Oral Tablet
35 BENDITA BEnznidazole New Doses Improved Treatment and Associations Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
36 Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
37 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
38 Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
39 Pharmacokinetic Drug-Drug Interaction Study Completed NCT03892213 Phase 1 Benznidazole;E1224
40 Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Completed NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
41 Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation Active, not recruiting NCT03708133 Phase 1 Nifurtimox (Lampit, BAYA2502)_Test;Nifurtimox (Lampit, BAYA2502)_Reference
42 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study Not yet recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
43 Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease Unknown status NCT02099903 Not Applicable
44 Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction Unknown status NCT02295215 Not Applicable
45 Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease Unknown status NCT01566617 Not Applicable
46 Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias Unknown status NCT01847378
47 Measurement of Antibodies in Adults With a History of Kawasaki Disease Unknown status NCT02853266
48 Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease Completed NCT02327052
49 MicroRNAs as Biomarkers in Patients With Chagas Disease Completed NCT01842880
50 Galectin-3 as a Biomarker in Patients With Chagas Disease Completed NCT01842854

Search NIH Clinical Center for Chagas Disease

Cochrane evidence based reviews: chagas disease

Genetic Tests for Chagas Disease

Anatomical Context for Chagas Disease

MalaCards organs/tissues related to Chagas Disease:

42
Heart, Testes, T Cells, Eye, Colon, Lymph Node, Skin

Publications for Chagas Disease

Articles related to Chagas Disease:

(show top 50) (show all 3193)
# Title Authors Year
1
Cerebral infarct topography of atrial fibrillation and Chagas disease. ( 30878634 )
2019
2
Elevated IL-17 levels and echocardiographic signs of preserved myocardial function in benznidazole-treated individuals with chronic Chagas' disease. ( 30528394 )
2019
3
Identification Key for the Chagas Disease Vectors of Five Brazilian States, Based on Cytogenetic Data. ( 30560768 )
2019
4
Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis. ( 30615644 )
2019
5
Cardiac Evaluation in the Acute Phase of Chagas' Disease with Post-Treatment Evolution in Patients Attended in the State of Amazonas, Brazil. ( 30624533 )
2019
6
Successful Aspects of the Co-administration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi. ( 30625275 )
2019
7
Improved DNA extraction technique from clot for the diagnosis of Chagas disease. ( 30633743 )
2019
8
American trypanosomiasis and Chagas disease: Sexual transmission. ( 30664986 )
2019
9
Imidazole derivatives as promising agents for the treatment of Chagas disease†. ( 30670432 )
2019
10
Effect of blockade of nitric oxide in heart tissue levels of Renin Angiotensin System components in acute experimental Chagas disease. ( 30684542 )
2019
11
A therapeutic preconceptional vaccine against Chagas disease: A novel indication that could reduce congenital transmission and accelerate vaccine development. ( 30703092 )
2019
12
Chagas Disease and the Kissing Bug: An Invisible Giant. ( 30704830 )
2019
13
Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. ( 30712412 )
2019
14
American Trypanosomiasis (Chagas Disease). ( 30712757 )
2019
15
Description of Triatomahuehuetenanguensis sp. n., a potential Chagas disease vector (Hemiptera, Reduviidae, Triatominae). ( 30728739 )
2019
16
Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease? ( 30731393 )
2019
17
Multiple Approaches to Address Potential Risk Factors of Chagas Disease Transmission in Northeastern Brazil. ( 30734691 )
2019
18
Burden of Chagas disease in Brazil, 1990-2016: findings from the Global Burden of Disease Study 2016. ( 30738925 )
2019
19
5-HT3A serotonin receptor in the gastrointestinal tract: the link between immune system and enteric nervous system in the digestive form of Chagas disease. ( 30747295 )
2019
20
Chagas disease, cardioembolic ischemic stroke, INR control and bleeding. ( 30758447 )
2019
21
First report of family clusters of Chagas disease seropositive blood donors in Mexico City and their epidemiological relevance. ( 30771283 )
2019
22
Increased serum gastrin in patients with different clinical forms of Chagas disease coinfected with Helicobacter pylori. ( 30785561 )
2019
23
Lack of evidence of seronegative infection in an endemic area of Chagas disease. ( 30785565 )
2019
24
Theft and Reception of Host Cell's Sialic Acid: Dynamics of Trypanosoma Cruzi Trans-sialidases and Mucin-Like Molecules on Chagas' Disease Immunomodulation. ( 30787935 )
2019
25
Characterization of digestive disorders of patients with chronic Chagas disease in Cochabamba, Bolivia. ( 30788442 )
2019
26
Modeling the Spatial Spread of Chagas Disease. ( 30805855 )
2019
27
Correction: Trypanosoma cruzi-specific IFN-γ-producing cells in chronic Chagas disease associate with a functional IL-7/IL-7R axis. ( 30807593 )
2019
28
The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole. ( 30807605 )
2019
29
Congenital Chagas disease: alert of research negligence. ( 30810649 )
2019
30
Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up. ( 30840798 )
2019
31
Agreement between upper endoscopy and esophagography in the diagnosis of megaesophagus in Chagas disease. ( 30843966 )
2019
32
Thermal Tolerance Plasticity in Chagas Disease Vectors Rhodnius prolixus (Hemiptera: Reduviidae) and Triatoma infestans. ( 30849174 )
2019
33
Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi. ( 30859917 )
2019
34
Assessing Parasite Load in Chagas Disease Patients by Quantitative Multiplex Real-Time PCR. ( 30868530 )
2019
35
Analytics of Functional Autoantibodies in Patients with Chagas Disease. ( 30868533 )
2019
36
Apolipoprotein A1 and Fibronectin Fragments as Markers of Cure for the Chagas Disease. ( 30868534 )
2019
37
Host-Derived Molecules as Novel Chagas Disease Biomarkers: Hypercoagulability Markers in Plasma. ( 30868535 )
2019
38
Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of α-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas Disease. ( 30868536 )
2019
39
Cytometric Bead Array (CBA) for Measuring Cytokine Levels in Chagas Disease Patients. ( 30868537 )
2019
40
Generation of T. cruzi-Specific Primary CD4+ T Cell Lines from Peripheral Blood Mononuclear Cells Isolated from Chagas Disease Patients. ( 30868538 )
2019
41
Trypanosoma cruzi-Specific T-Cell Responses to Monitor Treatment Efficacy in Chronic Chagas Disease. ( 30868539 )
2019
42
CD8+ T Cell Response to Trypanosoma cruzi Antigens during Chronic Chagas Disease. ( 30868540 )
2019
43
Fluorescence Proteomic Technology to Analyze Peripheral Blood Mononuclear Cells in Chronic Chagas Disease. ( 30868541 )
2019
44
Immune reactivity to Trypanosoma cruzi chimeric proteins for Chagas disease diagnosis in immigrants living in a non-endemic setting. ( 30871504 )
2019
45
Inhibition of ER Stress by 2-Aminopurine Treatment Modulates Cardiomyopathy in a Murine Chronic Chagas Disease Model. ( 30879276 )
2019
46
Corrigendum: Activation of Human CD11b+ B1 B-Cells by Trypanosoma cruzi-Derived Proteins Is Associated With Protective Immune Response in Human Chagas Disease. ( 30891038 )
2019
47
35 YEARS OF THE CLASSIFICATION OF REZENDE: THE IMPORTANCE OF ESOPHAGOGRAM IN THE CONTEXT OF CHAGAS DISEASE IN BRAZIL. ( 30892406 )
2019
48
Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients- Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. ( 30900295 )
2019
49
A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease. ( 30911415 )
2019
50
An Approach to The Acute Phase of Chagas' Disease: The Continuing Challenge it Presents in the 21(st) Century. ( 30916186 )
2019

Variations for Chagas Disease

Expression for Chagas Disease

Search GEO for disease gene expression data for Chagas Disease.

Pathways for Chagas Disease

Pathways related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.15 CALR CCL2 CCL3 CCR5 IFNG IL10
2
Show member pathways
13.97 ADRB1 CCL2 CCL3 CCR5 IL10 IL1B
3
Show member pathways
13.83 CCL2 CCL3 CCR5 IFNG IL10 IL1B
4
Show member pathways
13.66 CCL2 CCL3 IFNG IL10 IL1B IL2
5
Show member pathways
13.55 CCL2 CCL3 CCR5 IL10 IL1B IL2
6
Show member pathways
13.52 CCL2 CCL3 CCR5 IFNG IL10 IL1B
7
Show member pathways
13.45 CCL2 CCL3 CCR5 IL10 IL1B IL2
8
Show member pathways
13.14 CALR CCL2 CCL3 CCR5 IL1B IL6
9
Show member pathways
13.12 ACE CCL2 IL2 IL6 NTRK1 TGFB1
10
Show member pathways
13.1 ACE CALR CCL2 CCL3 IFNG IL10
11
Show member pathways
13.07 IL2 IL6 NTRK1 TLR2 TLR4 TNF
12
Show member pathways
13.03 CALR IFNG IL10 IL1B IL2 IL6
13 12.94 IFNG IL2 IL6 NOS2 NTRK1 TGFB1
14
Show member pathways
12.87 IL1B IL2 IL6 TGFB1 TLR2 TLR4
15
Show member pathways
12.83 IFNG IL1B IL6 TLR4 TNF
16
Show member pathways
12.78 CCL2 IFNG IL10 IL1B IL2 IL6
17 12.74 CCL2 IFNG IL10 IL1B IL2 TLR2
18
Show member pathways
12.73 IFNG IL10 IL1B IL2 IL6 TGFB1
19
Show member pathways
12.72 CCR5 IFNG IL10 IL1B IL2 IL6
20
Show member pathways
12.51 CCR5 IFNG IL10 IL2 IL6
21
Show member pathways
12.51 CCL2 IFNG IL1B IL2 IL6 TNF
22
Show member pathways
12.51 CCL2 IFNG IL1B IL6 TLR2 TNF
23
Show member pathways
12.49 IFNG IL1B IL6 NOS2 TLR4 TNF
24 12.47 CALR IL2 IL6 TGFB1 TNF
25
Show member pathways
12.46 IFNG IL10 IL1B IL2 IL6 NTRK1
26
Show member pathways
12.44 CCR5 IFNG IL10 IL1B NOS2 TGFB1
27 12.37 TGFB1 TLR2 TLR4 TNF
28
Show member pathways
12.37 IL1B IL6 NOS2 TLR2 TNF
29
Show member pathways
12.37 IFNG IL1B IL6 NOS2 TLR2 TLR4
30
Show member pathways
12.36 IL10 IL1B IL2 IL6 TNF
31
Show member pathways
12.36 ACE ADRB1 IL6 TGFB1 TNF
32 12.36 IFNG IL6 NOS2 TGFB1 TLR2 TLR4
33 12.36 IFNG IL10 IL1B IL6 NOS2 TGFB1
34
Show member pathways
12.34 IL6 TLR2 TLR4 TNF
35
Show member pathways
12.33 CCL2 CCL3 CCR5 IL1B TLR2 TLR4
36
Show member pathways
12.29 IFNG IL1B TLR4 TNF
37 12.27 IL10 IL1B IL6 TNF
38
Show member pathways
12.27 CCL2 CCL3 IFNG IL10 IL1B IL2
39
Show member pathways
12.25 IFNG IL1B IL6 TLR2 TLR4 TNF
40
Show member pathways
12.2 IFNG IL10 IL1B IL2 IL6 TGFB1
41 12.19 CCL2 IFNG IL1B TNF
42
Show member pathways
12.19 CCL3 CCR5 IFNG IL1B IL2 NOS2
43 12.17 IFNG IL10 IL2 IL6 TNF
44 12.15 IFNG IL1B TGFB1 TNF
45 12.15 CCL2 IL10 IL1B IL6 NOS2 TGFB1
46
Show member pathways
12.14 IL1B IL2 TLR2 TLR4
47 12.13 CCL3 IFNG IL1B IL6 TGFB1
48 12.1 CCL2 IL1B IL6 TGFB1 TNF
49 12.1 CCL2 IFNG IL1B IL2 IL6 NOS2
50 12.08 CCL2 IL1B IL6 TNF

GO Terms for Chagas Disease

Cellular components related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ACE CALR CCL2 CCL3 IFNG IL10
2 cell surface GO:0009986 9.7 CALR CCR5 NTRK1 TGFB1 TLR2 TLR4
3 external side of plasma membrane GO:0009897 9.65 ACE CALR CCR5 TLR4 TNF
4 extracellular space GO:0005615 9.4 ACE CALR CCL2 CCL3 IFNG IL10

Biological processes related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Name GO ID Score Top Affiliating Genes
1 cellular response to interferon-gamma GO:0071346 9.99 CCL2 CCL3 NOS2 TLR2 TLR4
2 response to organic substance GO:0010033 9.98 CALR IL10 TGFB1 TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 IL1B IL6 NTRK1 TGFB1 TLR2 TLR4
4 positive regulation of inflammatory response GO:0050729 9.97 CCL3 IL2 TLR2 TLR4 TNF
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 CCL2 CCL3 NTRK1 TGFB1 TLR4 TNF
6 regulation of insulin secretion GO:0050796 9.96 IFNG IL1B NOS2 TNF
7 cellular response to organic cyclic compound GO:0071407 9.96 CCL2 CCL3 IL1B TGFB1 TNF
8 inflammatory response GO:0006954 9.96 CCL2 CCL3 CCR5 IL10 IL1B IL6
9 cell chemotaxis GO:0060326 9.95 CCL2 CCL3 CCR5
10 defense response to Gram-negative bacterium GO:0050829 9.95 IL6 NOS2 TLR4
11 neutrophil chemotaxis GO:0030593 9.94 CCL2 CCL3 IL1B
12 positive regulation of JNK cascade GO:0046330 9.94 IL1B TLR4 TNF
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.94 IL6 TGFB1 TNF
14 cellular response to mechanical stimulus GO:0071260 9.94 IL1B TGFB1 TLR4
15 humoral immune response GO:0006959 9.94 CCL2 IFNG IL6 TNF
16 chemokine-mediated signaling pathway GO:0070098 9.93 CCL2 CCL3 CCR5
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 IFNG IL2 IL6
18 positive regulation of T cell proliferation GO:0042102 9.92 IL1B IL2 IL6
19 positive regulation of interferon-gamma production GO:0032729 9.92 IL1B IL2 TLR4 TNF
20 positive regulation of interleukin-6 production GO:0032755 9.92 IL1B IL6 TLR2 TLR4 TNF
21 cellular response to lipopolysaccharide GO:0071222 9.92 CCL2 CCR5 IL10 IL1B IL6 NOS2
22 positive regulation of tumor necrosis factor production GO:0032760 9.91 CCL3 TLR2 TLR4
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 IFNG IL1B TLR4 TNF
24 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 CALR IL1B TLR2 TLR4 TNF
25 response to hypoxia GO:0001666 9.9 NOS2 TGFB1 TLR2
26 negative regulation of fat cell differentiation GO:0045599 9.9 IL6 TGFB1 TNF
27 extrinsic apoptotic signaling pathway GO:0097191 9.9 IFNG TGFB1 TNF
28 monocyte chemotaxis GO:0002548 9.9 CCL2 CCL3 IL6
29 immune response GO:0006955 9.9 CCL2 CCL3 CCR5 IFNG IL10 IL1B
30 positive regulation of phagocytosis GO:0050766 9.89 CALR IL1B TNF
31 negative regulation of mitotic cell cycle GO:0045930 9.88 IL10 TGFB1 TNF
32 positive regulation of interleukin-8 production GO:0032757 9.88 IL1B TLR2 TLR4 TNF
33 negative regulation of interleukin-6 production GO:0032715 9.87 IL10 TLR4 TNF
34 negative regulation of neurogenesis GO:0050768 9.86 IL1B IL6 TNF
35 positive regulation of interleukin-12 production GO:0032735 9.86 IFNG TLR2 TLR4
36 positive regulation of protein complex assembly GO:0031334 9.85 IFNG TGFB1 TNF
37 positive regulation of glial cell proliferation GO:0060252 9.85 IL1B IL6 TNF
38 protein kinase B signaling GO:0043491 9.85 CCL2 CCL3 IL1B TGFB1 TNF
39 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.84 IFNG IL1B TNF
40 regulation of regulatory T cell differentiation GO:0045589 9.84 IFNG IL2 TGFB1
41 positive regulation of chemokine production GO:0032722 9.84 IL6 TLR2 TLR4 TNF
42 response to glucocorticoid GO:0051384 9.83 IL10 IL6 TNF
43 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.83 IL10 IL1B TNF
44 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.82 CCL2 TLR2 TLR4
45 cell activation GO:0001775 9.81 CCL3 TGFB1 TLR2
46 negative regulation of interleukin-17 production GO:0032700 9.8 IFNG TGFB1 TLR4
47 response to cholesterol GO:0070723 9.8 CCL3 CCR5 TGFB1
48 I-kappaB phosphorylation GO:0007252 9.77 TLR2 TLR4
49 positive regulation of immunoglobulin secretion GO:0051024 9.77 IL2 IL6
50 positive regulation of regulatory T cell differentiation GO:0045591 9.77 IL2 TGFB1

Molecular functions related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.28 CCL2 CCL3 IFNG IL10 IL1B IL2
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4
4 protein binding GO:0005515 10.19 ADRB1 CALR CCL2 CCL3 CCR5 IFNG

Sources for Chagas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....